Site Updates

Removed the mid-page overflow/max-height scroll container around the detox summary table so aids list straight on the page like supplements/binders details. Soft rounded cards and Edited styling unchanged.

Detail blocks redesigned as soft rounded cream cards with shadows and clearer hierarchy. Fixed purple underlined Edited links in Safari (visited-link color) site-wide. Same medical content.

Redesigned the How these aids may help section into real cards with nested panels, category badges, clearer hierarchy, and better mobile stacking. Same medical content.

Restyled the mRNA Detox page to match the rest of the site: warm theme, category chips, summary table, and detail cards. Same content.

New page listing every change to the site. The header now shows the date of the latest edit, and every page shows its own edited date. Both link here.

The Hulscher et al. cohort (Anticancer Research, Jun 2026) was fully retracted in Oct 2026 for methodological and analytical problems. Added the retraction notice.

Updated with the full Phase I result for HCQ + itraconazole: no large PSA drops, and Phase II was not pursued.

Published Phase 1 (NCT02644291): mebendazole alone was well tolerated, but showed limited benefit on its own.

Refreshed the HCQ + transarterial embolization trial for liver cancer (NCT05842174), now recruiting.

Randomized Phase II adding hydroxychloroquine to chemotherapy in relapsed ovarian cancer. Result: no benefit.

The 3-patient fenbendazole case series (Case Reports in Oncology, Jul 2025) was retracted in Jan 2026. Its entry now shows the retraction notice.

Removed 184 more non-cancer sources after a manual review. 1,327 sources remain.

Removed 111 sources that were not about cancer, found in a title-by-title audit of the source list.

Sources now show as cards by compound, with Show more buttons and a jump menu.

The category links at the top of Supplements now scroll to the right section of the table.

The Binders page got a new, cleaner layout.